Cardiol Therapeutics Beats Q1 Earnings Expectations

Got story updates? Submit your updates here. ›

Cardiol Therapeutics (NASDAQ:CRDL), a clinical-stage pharmaceutical company focused on developing treatments for cardiovascular disease, reported its first quarter 2026 financial results on Tuesday. The company posted a loss of $0.05 per share, beating the consensus analyst estimate of a $0.09 per share loss by $0.04.

Why it matters

Cardiol Therapeutics is working on innovative therapies for conditions like acute myocardial injury and heart failure, areas of significant unmet medical need. The company's ability to outperform expectations on its bottom line is an encouraging sign as it advances its pipeline of drug candidates.

The details

For the first quarter, Cardiol Therapeutics reported a net loss of $5.6 million, or $0.05 per share, compared to a net loss of $7.9 million, or $0.09 per share, in the same period a year earlier. The results beat the average analyst estimate of a $0.09 per share loss.

• Cardiol Therapeutics reported its Q1 2026 financial results on Tuesday, April 1, 2026.
• The company's shares traded up 1.5% on Wednesday, April 2, 2026 following the earnings release.

What’s next

Cardiol Therapeutics is expected to provide an update on the development of its lead drug candidate, CardiolRx, which is being evaluated for the treatment of acute myocardial injury and heart failure, in the coming months.